Eye Drops for Droopy Eyelids: What an FDA Side-Effect Database Shows About Oxymetazoline

A droopy upper eyelid, called ptosis, becomes more common with age. One option is a prescription eye drop, oxymetazoline hydrochloride 0.1%, approved by the FDA in January 2020 for this use. A study published in Ophthalmic Plastic & Reconstructive Surgery looked at real-world side-effect reports.

What the researchers did

A team searched the FDA Adverse Event Reporting System, a database where doctors, patients, and companies voluntarily report possible side effects, from the drop’s approval in January 2020 through April 2025. They found 306 patients with 658 reported events and used standard statistical methods to look for safety signals.

What they found

• All side effects already on the label showed up, most often eye-surface irritation, red eyes, temporary blurred vision, pain on application, and headache.
• New signals not on the label included a small number of reports of retinal or vitreous problems (such as retinal detachment, floaters, or bleeding inside the eye, about 3 reports each), dilated pupils, high blood pressure, and the drop becoming less effective over time.

How to read these results

A voluntary reporting database cannot prove a drug caused a problem or tell us how often it happens; it can only flag signals for further study. The authors said more research is needed to confirm these associations. Still, it is a useful reminder that even “cosmetic-feeling” drops are real medications.

Before trying eyelid-lifting drops

• Have the cause of the droop checked. Ptosis can sometimes signal nerve or muscle conditions that need different care.
• Tell your doctor about high blood pressure, heart disease, glaucoma, or medicines that affect blood pressure.
• Report new floaters, flashes, a curtain over your vision, or headaches right away.
• For a larger droop, an oculoplastic surgeon can discuss whether surgery is a better fit.

For more plain-language reading on eye health, see bettereyesightatanyage.com.

Source: Safety Analysis of Oxymetazoline Eye Drops for Blepharoptosis Using the FDA Adverse Event Reporting System (Ophthalmic Plastic & Reconstructive Surgery (PubMed), Nov–Dec 2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.